Ocugen (NASDAQ: OCGN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.090 | ||||||
REV | 10.370M | 0 | -10.370M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ocugen (NASDAQ: OCGN) through any online brokerage.
Other companies in Ocugen’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Eagle Pharmaceuticals (NASDAQ:EGRX), Altimmune (NASDAQ:ALT) and Immatics (NASDAQ:IMTX).
The latest price target for Ocugen (NASDAQ: OCGN) was reported by Roth Capital on Wednesday, June 15, 2022. The analyst firm set a price target for 8.00 expecting OCGN to rise to within 12 months (a possible 217.46% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Ocugen (NASDAQ: OCGN) is $2.52 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Ocugen.
Ocugen’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Ocugen.
Ocugen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.